用生物活性寡糖类向神经退行性疾病:机制和前景
Qinshuai Ni1, Shenghan Zhang2, Guorui Jia2
1Qingdao Traditional Chinese Medicine Hospital,Qingdao Hiser Hospital Affiliated of Qingdao University, Qingdao, Shandong, China.
International immunopharmacology
|September 18, 2025
概括
橄糖在治疗神经退行性疾病 (NDs) 方面表现有前途,通过准多种途径,如肠-大脑通信和神经炎症. 它们的结构决定了它们的神经保护作用,提供了潜在的疾病修饰疗法.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 全球老龄化增加了神经退行性疾病 (NDs) 的负担.
- 目前的ND治疗提供有限的症状缓解,并具有副作用.
- 需要针对疾病机制的新型治疗策略.
研究的目的:
- 对神经退行性疾病的寡糖的治疗潜力进行审查.
- 阐明寡糖的多方面的作用机制.
- 探索结构与活动之间的关系,以开发有效的干预措施.
主要方法:
- 关于寡糖和神经退行性疾病研究的文献综述.
- 对寡糖机制的分析,包括肠-大脑轴调节,神经炎症抑制,自增强和蛋白质聚合抑制.
- 基于甘氨酸键,分子大小和修饰的结构-活性关系的检查.
主要成果:
- 寡糖体显示了对NDs的多功能治疗潜力.
- 关键机制包括调节肠-大脑轴,减少神经炎症,增强自,抑制有毒蛋白质聚合.
- 橄糖神经保护受到结构特征的显著影响.
结论:
- 寡糖为新型神经退行性疾病治疗提供了一个有希望的途径.
- 它们针对多种病理途径的能力比传统治疗具有优势.
- 了解结构-活性关系对于设计疾病修饰的基于寡糖的干预措施至关重要.
更多相关视频
相关概念视频
Oligosaccharide Assembly
3.5K
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
3.5K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Alzheimer's Disease: Treatment
825
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
825
Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K


